Why SLE, Myositis, and SSc Are the New CAR-T Frontier

Systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM/myositis), and systemic sclerosis (SSc) represent a cluster of severe, refractory autoimmune diseases where conventional immunosuppression routinely fails the most affected patients. The patent and literature activity surveyed here reflects a growing recognition that chimeric antigen receptor (CAR)-based cellular therapies — primarily CD19-directed CAR-T cells — offer a potential immune reset for B-cell-driven autoimmunity, where standard-of-care agents such as rituximab, mycophenolate mofetil, and cyclophosphamide have left patients without adequate disease control.

Among retrieved results, SLE — including lupus nephritis and severe refractory SLE — is the most frequently named indication, appearing across at least 8 distinct patent families. Idiopathic inflammatory myopathies, encompassing dermatomyositis, polymyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy (IMNM), overlap myositis, inclusion body myositis, and cancer-associated myositis, are explicitly named alongside SSc in several of the most substantive CAR-T patent filings.

The central therapeutic rationale is straightforward: in conditions such as SLE and IIM, pathogenic autoreactive B cells and autoantibody-secreting plasmablasts sustain chronic tissue damage. CD19 is expressed on mature B cells and plasmablasts — the cellular source of anti-dsDNA and anti-Sm antibodies in SLE, anti-Jo-1 and anti-synthetase antibodies in myositis, and anti-Scl-70 and anti-centromere antibodies in SSc. Ablating this compartment with CD19-directed CAR-T cells is proposed to reset immune tolerance, according to PatSnap’s pipeline intelligence research.

Type I interferon signalling (IFN-α/β pathway) is highlighted as a central disease-driving pathway in SLE biology across multiple retrieved records. Although CAR-T filings in this dataset do not directly target this pathway, its centrality suggests that CAR-T strategies may eventually be evaluated in combination with type I IFN pathway modulation — a direction that organisations including WHO and academic consortia have flagged as a priority for severe SLE.

Seven Therapeutic Modalities Competing for the Autoimmune CAR-T Space

The CAR-T autoimmune pipeline is not a single-track race — at least seven distinct modalities are represented across the retrieved patent dataset, ranging from autologous CD19 CAR-T cells to engineered mesenchymal stromal cells. Each represents a different engineering philosophy and risk-benefit profile for patients with conditions such as lupus and myositis.

CD19-Directed CAR-T Cells (Autologous)

The dominant modality in this dataset is autologous, CD19-targeted CAR-T cell therapy for systemic autoimmune disease. Multiple patent families from Novartis AG and Juno Therapeutics, Inc. (a Bristol Myers Squibb company) describe manufacturing processes, dosing regimens, and clinical eligibility criteria. Juno Therapeutics’ filings describe a manufacturing workflow involving leukapheresis from individual patients, immunoaffinity-based enrichment of CD4+ and CD8+ T cells, and administration of doses ranging from 1×10⁶ to 50×10⁶ CAR-positive viable T cells. Novartis AG’s patent families span multiple jurisdictions and explicitly claim manufacturing of CAR-T cells with “minimal ex vivo expansion” — described as less than 1 day, or zero ex vivo expansion — as a product differentiation strategy.

Hypoimmunogenic / Allogeneic CAR-T Cells

Sana Biotechnology, Inc. has filed across multiple jurisdictions on engineered hypoimmunogenic CAR-T cells that exhibit reduced expression of MHC class I and/or MHC class II HLAs and T-cell receptors, enabling off-the-shelf allogeneic use. These cells exogenously express the “don’t eat me” signal CD47 to suppress host macrophage-mediated phagocytosis, with claimed applications spanning autoimmune and inflammatory diseases.

CAR-Treg Cells

The Regents of the University of California and Monash University describe CAR-expressing regulatory T cells (Tregs) engineered to target disease-relevant autoantigens to induce localised immunosuppression rather than broad B-cell depletion. The Monash University filing describes Treg populations expressing TCR-based binding proteins specific for Ro60, MPO, and Smith protein — autoantigens directly implicated in SLE — as targets for antigen-specific Treg recruitment rather than elimination.

CAR-NK Cells, Orthogonal Systems, and Beyond

Nkarta, Inc. describes CD19-directed CAR-NK cells for SLE and lupus nephritis, with in vitro cytotoxicity data against CD19+ PBMC subsets and a detailed dosing cycle schema. Synthekine, Inc. describes an orthogonal CAR-T approach in which an engineered orthogonal IL-2 ligand selectively activates only CAR-T cells expressing an engineered orthogonal CD122 (IL-2Rβ) receptor — claimed to support CAR-T activity in the absence of prior lymphodepletion. TR1X, Inc. describes CD4+ T cells co-expressing IL-10 and a chimeric antigen receptor for immune tolerisation. Mayo Clinic (Mayo Foundation for Medical Education and Research) describes engineered mesenchymal stromal cells (CAR-MSC) with elevated levels of immunosuppressive polypeptides, with in vivo data in mouse xenograft models.

Assignee Landscape: Who Is Filing and Where

Commercial patent activity overwhelmingly dominates over academic literature in this dataset. Novartis AG is the highest-volume filer, with at least 5 retrieved patent records spanning WO, AU, CN, JP, and BR jurisdictions — all pending or active, with dates ranging from 2024 to 2025. Juno Therapeutics, Inc. has multiple filings across WO, IL, AU, JP, and CN jurisdictions from 2024 to 2026, with the most clinically detailed retrieved data of any assignee.

Sana Biotechnology, Inc. is the primary filer on the hypoimmunogenic/allogeneic CAR-T angle, with WO and AU filings from 2023–2024. Synthekine, Inc. represents a unique engineering angle — orthogonal cytokine systems — in a 2025 WO filing. The Regents of the University of California and Monash University represent academic patent filers pursuing CAR-Treg strategies, including antigen-specific approaches using SLE-relevant autoantigens such as Ro60, MPO, and Smith protein. TR1X, Inc. and Nkarta, Inc. represent smaller biotech entrants with IL-10/CAR-T and CAR-NK platforms, respectively. The Trustees of the University of Pennsylvania and The Children’s Hospital of Philadelphia contribute foundational CAR-T engineering patents that underpin the broader field, with autoimmune applications as secondary claims, according to PatSnap’s patent analytics.

Clinical Translation Signals and What the Patent Detail Reveals

The most substantive clinical translation signals in this dataset come from Juno Therapeutics’ patent filings — specifically a Japanese national phase filing that includes Example 3, describing administration of autologous anti-CD19 CAR+ T cells as monotherapy in subjects with severe refractory SLE and lupus nephritis. The level of clinical detail embedded in these patents is a meaningful indicator of development stage.

“Eligibility criteria cited include BILAG grade A or ≥2 BILAG B moderate scores in major organs, and documented inadequate response to ≥2 prior treatments — including anti-CD20 antibodies, MMF, cyclophosphamide, belimumab, rituximab, anifrolumab, azathioprine, methotrexate, cyclosporin, and voclosporin.”

The Juno WO filing from 2024 explicitly defines dose ranges of 1×10⁶ to 50×10⁶ CAR-positive viable T cells, covering both severe and moderate systemic autoimmune disease. The disease list includes SLE, Sjögren’s syndrome, progressive systemic sclerosis (scleroderma), and idiopathic inflammatory myositis. Pharmacokinetic monitoring of CAR+ T cell populations — at thresholds of greater than 1, greater than 5, or greater than 10 cells per microlitre in peripheral blood — is specified, consistent with at least IND-enabling or early-phase clinical evaluation.

Novartis’s CN and JP filings describe CAR-T manufacturing with “minimal ex vivo expansion” — less than 1 day, or zero ex vivo expansion — a manufacturing claim that may reflect lessons from early clinical experience regarding the importance of T-cell stemness for durable responses. This is consistent with trends observed in the broader CAR-T oncology field, where organisations such as the FDA have increasingly scrutinised manufacturing process claims in biologics applications.

Synthekine’s orthogonal CAR-T filing for lupus specifically claims efficacy “in the absence of prior lymphodepletion” — a clinically meaningful differentiation point. Lymphodepletion (typically fludarabine/cyclophosphamide conditioning) carries morbidity risk in autoimmune patients who may already be immunocompromised or cytopaenic. This is a recognised concern flagged in the broader cell therapy literature reviewed by bodies including the EMA in its advanced therapy medicinal product (ATMP) guidance.

Combination Strategies and Emerging Engineering Directions

The retrieved patent dataset signals several combination strategies that address the two primary technical risks identified in this space: cytokine release syndrome (CRS) and manufacturing scalability. These combination approaches are not peripheral — they are central to making CAR-T therapy viable in an autoimmune patient population that differs meaningfully from the oncology patients in whom CAR-T was first developed.

CAR-T + JAK-STAT Inhibitor for CRS Mitigation

University of Pennsylvania and physician-inventor Saar Gill describe combining CD19 or CD123 CAR-T therapy with JAK-STAT inhibitors (e.g., ruxolitinib) or BTK inhibitors to prevent cytokine release syndrome. CRS is a well-recognised safety concern for CAR-T in both oncology and autoimmune settings, and this combination strategy signals an emerging safety management approach applicable to autoimmune indications. CD123 (IL-3 receptor alpha chain) is also targeted in the context of plasmacytoid dendritic cell (pDC) biology relevant to the type I interferon axis in SLE.

Hypoimmunogenic CAR-T (CD47 + MHC Deletion) for Off-the-Shelf Use

Sana Biotechnology’s platform — engineering CAR-T cells for simultaneous MHC class I/II deletion and CD47 overexpression — signals an emerging direction toward allogeneic (off-the-shelf) CAR-T for autoimmune disease. The 2024 AU filing is a recent extension of the 2023 WO filing, suggesting continued prosecution activity. If autologous CAR-T demonstrates clinical proof-of-concept in lupus or myositis, allogeneic platforms may scale more broadly — making current IP positions in this sub-segment strategically valuable.

IIM with ILD as a Specific Clinical Subpopulation

Multiple retrieved patent records — particularly from Novartis and Juno Therapeutics — specifically name “antisynthetase syndrome with ILD” as a distinct clinical subpopulation warranting CAR-T therapy. Rapidly progressive SSc “with significant lung involvement” is similarly foregrounded in Novartis filings. This signals emerging interest in CAR-T for particularly severe and treatment-refractory myositis and SSc subtypes with significant unmet need, a priority area also recognised by NIAID in its autoimmune disease research agenda.

Strategic Implications for IP, R&D, and Drug Development

The CAR-T autoimmune patent landscape carries several clear strategic implications for IP counsel, R&D leaders, and drug developers operating in this space. The signals from this dataset point to a field in rapid transition — from oncology-adjacent to autoimmune-primary IP — with meaningful differentiation opportunities in manufacturing, safety, and patient selection.

• CD19 CAR-T for refractory autoimmune disease is rapidly transitioning from oncology-adjacent to autoimmune-primary IP. Novartis and Juno Therapeutics (BMS) have filed broad, multi-jurisdictional patent portfolios explicitly naming SLE, SSc, and IIM/myositis as target indications — with Juno’s filings containing clinical-grade detail consistent with active or planned trials. IP strategists should monitor claim scope for manufacturing process claims versus clinical indication claims.
• The lymphodepletion question is a key differentiator and IP opportunity. Synthekine’s orthogonal cytokine approach targets CAR-T use without prior lymphodepletion conditioning — a clinically meaningful distinction in autoimmune patients with cytopenia or infection risk. Novel cytokine engineering claims in this space may be a defensible IP moat.
• Allogeneic platforms (hypoimmunogenic CAR-T, CAR-NK) are positioned as the next wave. Sana Biotechnology and Nkarta represent early movers in allogeneic/off-the-shelf approaches for autoimmune disease. If autologous CAR-T demonstrates clinical proof-of-concept, allogeneic platforms may scale more broadly — making current IP positions in this sub-segment strategically valuable.
• IIM with ILD and rapidly progressive SSc represent high-priority unmet need niches. Multiple retrieved filings specifically enumerate these severe subtypes. Academic researchers and drug developers should note that IIM (especially antisynthetase syndrome with ILD) and SSc with pulmonary involvement appear to be gaining traction as CAR-T development targets beyond SLE.
• CRS and manufacturing scalability are the primary technical risks flagged in this dataset. The co-development of CAR-T + kinase inhibitor strategies for CRS management, and the explicit manufacturing innovation claims around “minimal ex vivo expansion” in Novartis filings, reveal that safety management and manufacturing speed are recognised bottlenecks driving further combination patent filings and process patents in this space.

“Allogeneic platforms (hypoimmunogenic CAR-T, CAR-NK) are positioned as the next wave — if autologous CAR-T demonstrates clinical proof-of-concept, current IP positions in the allogeneic sub-segment become strategically valuable.”

The dataset also contains very limited academic literature specifically on CAR-T in autoimmune disease — retrieved literature records address immune checkpoint-related arthritis and DMARD responses, which are adjacent but not CAR-T-specific. This gap between commercial patent activity and published academic evidence is itself a signal: the field is moving faster in IP than in peer-reviewed publication, consistent with competitive dynamics observed in other cell therapy areas tracked by organisations such as ISCT (the International Society for Cell & Gene Therapy).